Multiparametric MRI (mpMRI) has revolutionized prostate cancer diagnosis and risk stratification, but the question remains regarding what it is that we see (or don’t see) on mpMRI. A new study by Houlahan and colleagues now offers insight into the molecular characteristics of a tumour that influence mpMRI visibility.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hamdy, F. C. et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).
Bill-Axelson, A. et al. Radical prostatectomy or watchful waiting in prostate cancer - 29-year follow-up. N. Engl. J. Med. 379, 2319–2329 (2018).
Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).
Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).
Houlahan, K. E. et al. Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer. Eur. Urol. https://doi.org/10.1016/j.eururo.2018.12.036 (2019).
Li, H. et al. Dynamics of angiogenesis and cellularity in rabbit VX2 tumors using contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging. Oncol. Lett. 15, 2978–2984 (2018).
Liang, S. et al. Information-based ranking of 10 compartment models of diffusion-weighted signal attenuation in fixed prostate tissue. NMR Biomed. 29, 660–671 (2016).
Devine, W. et al. Simplified luminal water imaging for the detection of prostate cancer from multiecho T2 MR images. J. Magn. Reson. Imaging https://doi.org/10.1002/jmri.26608 (2018).
Martin, D. T. et al. Prostate cancer genomic classifier relates more strongly to gleason grade group than prostate imaging reporting and data system score in multiparametric prostate magnetic resonance imaging-ultrasound fusion targeted biopsies. Urology 125, 64–72 (2019).
Moore, C. M. et al. The effect of dutasteride on magnetic resonance imaging defined prostate cancer: MAPPED-a randomized, placebo controlled, double-blind clinical trial. J. Urol. 197, 1006–1013 (2017).
Acknowledgements
M.E. receives research support from the United Kingdom’s National Institute of Health Research (NIHR) and the University College London Hospital (UCLH)–UCL Biomedical Research Centre. He has been an NIHR Senior Investigator since 2013.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Emberton, M. To see or not to see — what renders prostate cancer visible?. Nat Rev Urol 16, 274–275 (2019). https://doi.org/10.1038/s41585-019-0167-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0167-5